Abstract: A bispecific antibody including a first domain which specifically binds to a mutant calreticulin protein and a second domain which specifically binds to a CD3 antigen. A pharmaceutical composition including the bispecific antibody or a functional fragment thereof. A diagnostic method for a myeloproliferative neoplasm, including detecting a polypeptide in a biological sample with the bispecific antibody.

Abstract: A process for preparing a diazabicyclooctane compound represented by the following formula (I): wherein A represents RcO—; B represents NH or NC1-6 alkyl; C represents a benzyl group; Rc represents a C1-6 alkyl group; A is substituted with one substituent Fn1, wherein Fn1 represents an azetidine group; the process including: (a) silylating the compound represented by the following formula (IV-c): wherein in the formula (IV-c), OBn represents benzyloxy, and (b) carrying out an intramolecular urea formation reaction.

Abstract: A process for preparing a diazabicyclooctane compound represented by the following formula (I): wherein A represents RcO—; B represents NH or NC1-6 alkyl; C represents a benzyl group; Rc represents a C1-6 alkyl group; A is substituted with one substituent Fn1, wherein Fn1 represents an azetidine group; the process including: (a) silylating the compound represented by the following formula (IV-c): wherein in the formula (IV-c), OBn represents benzyloxy, and (b) carrying out an intramolecular urea formation reaction.

Abstract: A novel use of agonist to PD-1 is developed. Provided is a pharmaceutical composition for treating or preventing Th2-mediated diseases, the composition comprising an effective amount of a PD-1 agonist.

Abstract: Provided are crystals of 1-((2-(3,6-diazabicyclo[3.1.

Abstract: A crystalline form I of a compound represented by Formula (VII-1): having characteristic peaks appearing at lattice spacing (d) of 7.34, 5.66, 5.53, 5.30, 5.02, 4.66, 4.37, 4.28, 4.06, 3.68, 3.62, 3.47, 3.36, 3.30, 3.16, 3.11, 3.03, 2.99 and 2.50 ? in the powder X-ray diffraction pattern.

Abstract: A control agent comprising, as an active ingredient, a specific quinoline derivative compound such as 8-fluoro-2,3-dimethyl-6-(1,1-dimethylethyl)-4-(methylcarbonyl)oxyquinoline, azoxystrobin, picoxystrobin, pyraclostrobin, kresoxim-methyl, trifloxystrobin, metominostrobin, orysastrobin, famoxadone, fluoxastrobin, pyribencarb, cyazofamid, amisulbrom, flutolanil, mepronil, isofetamid, fluopyram, carboxin, thifluzamide, fluxapyroxad, furametpyr, penflufen, penthiopyrad, boscalid, diflumetorim, fluazinam, ferimzone, fenpyroximate, or an acid addition salt of any of these compounds shows an excellent controlling effect on Mesostigmata mites.

Abstract: A crystalline form I of a compound represented by Formula (VII-1): having characteristic peaks appearing at lattice spacing (d) of 7.34, 5.66, 5.53, 5.30, 5.02, 4.66, 4.37, 4.28, 4.06, 3.68, 3.62, 3.47, 3.36, 3.30, 3.16, 3.11, 3.03, 2.99 and 2.50 ? in the powder X-ray diffraction pattern.

Abstract: A diagnostic, preventive, or therapeutic agent may be used for a myeloproliferative neoplasm. An antibody or a functional fragment thereof that binds to a cleaved mutant CALR protein, may include an antigen-recognition site in (a) a polypeptide chain having an amino acid sequence set forth in SEQ ID NO: 1 or (b) a polypeptide chain having an amino acid sequence having deletion, substitution, or addition of one to several amino acids in SEQ ID NO: 1; and a diagnostic, preventive, or therapeutic agent for a myeloproliferative neoplasm containing the antibody.

Abstract: [Problem] The present invention provides a method for producing and isolating a target quinolone derivative using general industrial facilities with high purity. [Solving means] The present invention also provides a method for producing a quinolone derivative, the method including reacting a ketone with an anthranilic acid derivative using an aluminum halide and removing the aluminum halide under basic conditions.

Abstract: A Mesostigmata mite control composition comprising, as active ingredients: a specific quinoline derivative compound such as 8-fluoro-2,3-dimethyl-6-(1,1-dimethylethyl)-4-(methylcarbonyl)oxyquinoline; and at least one of other pest control agents exhibits an excellent control effect on Mesostigmata mites.

Abstract: A process for preparing a diazabicyclooctane compound represented by the following formula (I): wherein A represents RcO—; B represents NH or NC1-6 alkyl; C represents a benzyl group; Rc represents a C1-6 alkyl group; A is substituted with one substituent Fn1, wherein Fn1 represents an azetidine group; the process including: (a) silylating the compound represented by the following formula (IV-c): wherein in the formula (IV-c), OBn represents benzyloxy, and (b) carrying out an intramolecular urea formation reaction.

Abstract: An aqueous suspension-form pesticidal composition comprising: at least one pesticidal active ingredient selected from the group consisting of amine derivatives represented by the following general formula (1) and salts thereof; a highly-purified and partially-desulfonated lignosulfonate; and an aqueous dispersion medium [In the general formula (1), Ar represents a pyridyl group optionally substituted with a halogen atom or the like, or a pyrimidyl group optionally substituted with a halogen atom or the like; R1 represents a hydrogen atom or a C1-6 alkyl group; Y represents a hydrogen atom or the like; and R2 represents a C1-6 alkyl group substituted with a halogen].

Abstract: A therapeutic agent for treating at least one disease selected from the group consisting of inflammatory diseases, autoimmune diseases, fibrotic diseases, and cancer diseases, comprising: at least one selected from the group consisting of a compound represented by the following general formula (1) and pharmacologically acceptable salts thereof as an active ingredient. [In the formula (1), R1 and R2 may be the same or different and each represents a hydrogen atom, a halogen atom, a hydroxyl group, a carboxy group, a cyano group, an optionally substituted C1-6 alkyl group et al.; R3 represents a hydrogen atom; R4 represents an optionally substituted 4- to 10-membered monocyclic heterocyclic group containing 1 to 4 heteroatoms selected from an oxygen atom, a nitrogen atom, and a sulfur atom; X represents a group represented by the following formula: —CH2—, —CH2—CH2—, —CH2—CH2—CH2—, or —CH2—O—CH2—; and Z represents a hydrogen atom or a hydroxyl group.

Abstract: A compound represented by the following general formula (I) or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutical composition thereof, and the use thereof to prevent or treat infectious diseases and a method to prevent or treat infectious diseases using those regimen are disclosed. The compound represented by formula (I) has an antibacterial activity against both gram-positive and gram-negative bacteria, and is useful in the prevention or treatment of infectious diseases caused by these bacteria.

Abstract: It has been found that a bacteriophage specified by accession number NITE BP-693 and a bacteriophage specified by accession number NITE BP-694 have lytic activity against Staphylococcus hyicus, Staphylococcus chromogenes, and the like, which has made it possible to provide a composition for lysing these staphylococci, a composition for treating or preventing a disease caused by these staphylococci, and the like.

Abstract: A process for preparing a diazabicyclooctane compound represented by the following formula (I): wherein A represents RcO—; B represents NH or NC1-6 alkyl; C represents a benzyl group; Rc represents a C1-6 alkyl group; A is substituted with one substituent Fn1, wherein Fn1 represents an azetidine group; the process including: (a) silylating the compound represented by the following formula (IV-c): wherein in the formula (IV-c), OBn represents benzyloxy, and (b) carrying out an intramolecular urea formation reaction.

Abstract: A process for producing crystals of a compound represented by the following formula (I): by crystallizing the compound from an aqueous solution containing the compound and an inorganic salt, such as sodium chloride. Such crystals can be subjected to lyophilization to provide a lyophilized composition having a desirable storage stability.

Abstract: Disclosed is a wettable agrochemical composition comprising an agrochemical active component (A), which is a compound represented by the following formula (I) or an agriculturally and horticulturally acceptable acid addition salt thereof, one or more additives, and one or more surfactants, the wettable agrochemical composition being solid at 30° C. This wettable agrochemical composition has excellent physical properties of the formulation and storage stability.

Abstract: A plant disease control agent which contains a compound represented by formula (1) as an active ingredient.